4Q preview: Amgen, Biogen, BMS, Celgene, Novartis, Pfizer and Roche
This article was originally published in Scrip
Executive Summary
The full-year reporting season began on 21 January with Johnson & Johnson reporting a strong showing from pharma sales (helped from an expected short-lived boost from its hepatitis C newcomer Olysio (simeprevir). Its fourth-quarter figures already showed the effects of "currency headwinds" that are expected to impact many in its pharma peer set in 2015. It warned that foreign exchange shifts with the recent strong appreciation of the US dollar will weigh on its 2015 figures. Goldman Sachs analysts believe big US pharma companies will take a 4-6% hit from currency headwinds in 2015, with about 37-50% of the top line hit flowing to EPS.
You may also be interested in...
J.P. Morgan Highlights: Major M&A Missing, But Key Takeaways For Year Ahead
The annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2022’s meeting of industry leaders, investors and technology creators.
Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate
Clive Dix was awarded Scrip’s Lifetime Achievement honor jointly with his long-term colleague and friend Dame Kate Bingham in December 2021. With more than 30 years’ experience in pharma and biotech, Dix has seen the industry evolve and take on many challenges. He spoke to In Vivo about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.
Experience Counts For VC Success: HealthCap Hits 25 Year Mark
VC Playbook: The fundamentals do not change in life sciences investing – good science, unmet need and social responsibility.